An early feasibility study of the Nativis Voyager

Authors

Charles Cobbs, Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Medical Center, Seattle, WA 98122, USA.Follow
Edward McClay
J Paul Duic
L Burt Nabors
Donna Morgan Murray
Santosh Kesari, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA 90404, USA.Follow

Document Type

Article

Publication Date

12-14-2018

Publication Title

CNS Oncol

Keywords

clinical trials; medical device; novel therapy; recurrent GBM; ultra-low radiofrequency energy; brain tumor

Abstract

AIM: Evaluation of the Nativis Voyager

MATERIALS & METHODS: Voyager is a noninvasive, nonthermal, nonionizing and portable investigational device which delivers ultra-low radio frequency energy (ulRFE

RESULTS: Data from the first 11 patients treated are reported here. Median progression-free survival was 10 weeks in the V arm and 16 weeks in the V + SoC arm. Median overall survival was 16 months in V arm and 11 months in the V + SoC arm. No serious adverse events associated with the device were reported.

CONCLUSION: These data suggest that the Voyager is safe and feasible for the treatment of rGBM.

Clinical Institute

Neurosciences (Brain & Spine)

Clinical Institute

Cancer

Department

Neurosciences

Department

Oncology

Recommended Citation

Cobbs, Charles; McClay, Edward; Duic, J Paul; Nabors, L Burt; Morgan Murray, Donna; and Kesari, Santosh, "An early feasibility study of the Nativis Voyager" (2018). Articles, Abstracts, and Reports. 918.
https://digitalcommons.providence.org/publications/918